New immunotherapy drug for advanced esophageal cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new experimental drug that combines two ways to boost your immune system to fight cancer. It is for people with advanced esophageal cancer whose cancer didn't respond to previous immunotherapy and chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of esophageal cancer called squamous cell carcinoma that is advanced or has spread.
- Your cancer grew or returned after you already had both immunotherapy and platinum-based chemotherapy.
- You are between 18 and 75 years old.
- You are able to take care of yourself and are not bedridden.
- Your major organs (like liver and kidneys) are working well enough, based on recent tests.
- You agree to use effective birth control during the study and for 6 months after the last dose (if applicable).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called BL-B01D1 combined with an immune therapy (tislelizumab) and sometimes chemotherapy against standard chemotherapy for esophageal squamous cell carcinoma that cannot be surgically removed. The goal is to see if this new combination works better and is safer than current treatment.
This trial is testing a new immunotherapy drug (QL1706) combined with an anti-inflammatory drug (celecoxib) for advanced esophageal cancer that has progressed after previous immunotherapy. It may help slow down tumor growth and give you more treatment options.
This trial studies investigational cancer medicines, either alone or along with pembrolizumab, for people with advanced esophageal squamous cell cancer whose cancer has grown despite prior immune and platinum-based treatment. It may offer a new option after standard therapy has not worked.
This trial tests a new combination of two drugs (QL1706 and lenvatinib) for people whose esophageal cancer has progressed after initial immunotherapy. The goal is to see if this combination can help shrink tumors or slow cancer growth.
This trial tests a combination of three drugs (adebrelimab, apatinib, and a chemotherapy pill) for people with advanced esophageal cancer whose previous immunotherapy treatment stopped working. The goal is to see if this new combination can help the immune system fight the cancer again.
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
Hear when a new Esophageal Squamous Carcinoma Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.